Allogene Therapeutics (ALLO) Other Non Operating Income (2018 - 2026)

Allogene Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at $212000.0 in Q1 2026.

• Quarterly Other Non Operating Income rose 130.43% year-over-year to $212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335000.0 (up 111.56% YoY) and the FY2025 annual result came in at $215000.0, up 105.48% from the prior year.
• Other Non Operating Income declined to $212000.0 in Q1 2026 per ALLO's latest filing, from $247000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $2.1 million in Q1 2023 and troughed at -$6.9 million in Q4 2023.
• A 5-year average of -$1.5 million and a median of -$929000.0 in 2024 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income sank 651.22% in 2022, then soared 130.43% in 2026.
• Over 5 years, Other Non Operating Income stood at -$3.6 million in 2022, then plunged by 90.65% to -$6.9 million in 2023, then jumped by 71.85% to -$2.0 million in 2024, then jumped by 112.65% to $247000.0 in 2025, then decreased by 14.17% to $212000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $212000.0, $247000.0, and -$81000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.